Yam, Clinton
Mittendorf, Elizabeth A.
Garber, Haven R.
Sun, Ryan
Damodaran, Senthil
Murthy, Rashmi K.
Ramirez, David
Karuturi, Meghan
Layman, Rachel M.
Ibrahim, Nuhad
Rauch, Gaiane M.
Adrada, Beatriz E.
Candelaria, Rosalind P.
White, Jason B.
Ravenberg, Elizabeth
Clayborn, Alyson
Ding, Qing Qing
Symmans, W. Fraser
Prabhakaran, Sabitha
Thompson, Alastair M.
Valero, Vicente
Tripathy, Debu
Huo, Lei
Moulder, Stacy L.
Litton, Jennifer K. http://orcid.org/0000-0001-8390-4985
Funding for this research was provided by:
Conquer Cancer Foundation (2020CDABC-5423266503, 12266)
University of Texas MD Anderson Cancer Center (Allison, Brian Grove Endowed Fellowship for Breast Medical Oncology, Susan Papizan Dolan Fellowship in Breast Oncology)
Genentech
Still Water Foundation
Brigham and Women's Hospital (Rob, Karen Hale Distinguished Chair in Surgical Oncology)
Article History
Received: 24 January 2023
Accepted: 30 March 2023
First Online: 15 April 2023
Declarations
:
: C.Y. has received research funding (to the institution) from Genentech, Gilead, BostonGene, Sanofi, Amgen, Pfizer, Astellas, Novartis and has served on advisory boards for Gilead. E.A.M. has received research support from Roche/Genentech (via the SU2C grant), and Gilead, has served on steering committees for Bristol Myers Squib, Lilly, Roche/Genentech, and has served on scientific advisory boards for AstraZeneca, Exact Sciences (formerly Genomic Health), Merck, Roche/Genentech. R.K.M. has received honoraria from Puma biotechnology, Seattle genetics, Genetech, Novartis, and Astrazeneca; has served in a consulting or advisory role for Sanofi, Novartis, AstraZeneca, Pfizer, Genentech/Roche, Seattle Genetics, Puma Biotechnology; has received research funding (to the institution) from Seattle Genetics, Genetch/Roche, Pfizer, Daiichi Sankyo, AstraZeneca, EMD Serono; has received travel, accommodations, expenses from Genentech, Seattle Genetics. E.A.R. is currently employed at Eli Lilly (previously employed by MD Anderson at the time the study was conducted). W.F.S. is a co-inventor/patent of US Patent No. 11,459,617 “Targeted measure of transcriptional activity related to hormone receptors” issued on 10/4/2022 (applicant proprietor: University of Texas MD Anderson Cancer Center. Licensed to Delphi Diagnostics, Inc. and has co-founder equity from Delphi Diagnostics, Inc. A.T. is related by marriage to an employee of Eli Lilly. D.T. has received research support (to the institution) from Novartis, Pfizer, Polyphor and has served as a consultant to AstraZeneca, Glaxosmithkline, Gilead, Oncopep, Pfizer, Novartis, AMBRX, Personalis, Sermonix, Stemline-Menarini, Puma Biotechnology. S.L.M. is currently employed by Eli Lilly (previously employed by MD Anderson at the time the study was conducted). J.K.L. has received grant or research support from Novartis, Medivation/Pfizer, Genentech, GSK, EMD-Serono, AstraZeneca, Medimmune, Zenith, Jounce; participated in Speaker’s Bureau for MedLearning, Physician’s Education Resource, Prime Oncology, Medscape, Clinical Care Options; received honoraria from UpToDate; served on advisory committees or review panels for AstraZeneca, Ayala, Pfizer (all uncompensated), NCCN, ASCO, NIH, PDQ, SITC Breast Committee, SWOG Breast Committee. All other authors declare that they have no relevant conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.